ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease
January 17, 2022Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate... -
China’s First Innovative Drug for Alzheimer’s Disease: GV-971 Marketed at RMB895
January 06, 2020The innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) has been officially marketed in China, which is priced at RMB895/box and has attracted much attention of the pharmaceutical practitioners.
Pharma Sources Insight January 2025
